Orion Infusion Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
Orion Infusion has been growing earnings at an average annual rate of 2.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 0.6% per year. Orion Infusion's return on equity is 14.4%, and it has net margins of 5.2%.
Key information
2.6%
Earnings growth rate
2.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 0.6% |
| Return on equity | 14.4% |
| Net Margin | 5.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Orion Infusion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 825 | 43 | 250 | 0 |
| 30 Sep 23 | 821 | 42 | 249 | 0 |
| 30 Jun 23 | 810 | 42 | 248 | 0 |
| 31 Mar 23 | 825 | 42 | 254 | 0 |
| 31 Dec 22 | 823 | 44 | 245 | 0 |
| 30 Sep 22 | 815 | 41 | 243 | 0 |
| 30 Jun 22 | 830 | 43 | 247 | 0 |
| 31 Mar 22 | 846 | 34 | 248 | 0 |
| 31 Dec 21 | 832 | 32 | 251 | 0 |
| 30 Sep 21 | 806 | 33 | 242 | 0 |
| 30 Jun 21 | 727 | 28 | 216 | 0 |
| 31 Mar 21 | 652 | 24 | 198 | 0 |
| 31 Dec 20 | 617 | 22 | 189 | 0 |
| 30 Sep 20 | 654 | 22 | 198 | 0 |
| 30 Jun 20 | 741 | 30 | 224 | 0 |
| 31 Mar 20 | 797 | 39 | 239 | 0 |
| 31 Dec 19 | 858 | 41 | 262 | 0 |
| 30 Sep 19 | 849 | 45 | 260 | 0 |
| 30 Jun 19 | 810 | 40 | 247 | 0 |
| 31 Mar 19 | 877 | 41 | 267 | 0 |
| 31 Dec 18 | 807 | 40 | 239 | 0 |
| 30 Sep 18 | 795 | 38 | 232 | 0 |
| 30 Jun 18 | 754 | 33 | 220 | 0 |
| 31 Mar 18 | 657 | 29 | 180 | 0 |
| 31 Dec 17 | 686 | 33 | 190 | 0 |
| 30 Sep 17 | 663 | 31 | 183 | 0 |
| 30 Jun 17 | 680 | 31 | 186 | 0 |
| 31 Mar 17 | 696 | 92 | 185 | 0 |
| 31 Dec 16 | 710 | 88 | 190 | 0 |
| 30 Sep 16 | 731 | 104 | 197 | 0 |
| 30 Jun 16 | 730 | 107 | 197 | 0 |
| 31 Mar 16 | 700 | 40 | 190 | 0 |
| 31 Dec 15 | 705 | 42 | 189 | 0 |
| 30 Sep 15 | 656 | 29 | 175 | 0 |
| 30 Jun 15 | 663 | 28 | 178 | 0 |
| 31 Mar 15 | 695 | 27 | 192 | 0 |
| 30 Jun 14 | 657 | 74 | 184 | 0 |
| 31 Mar 14 | 600 | 74 | 217 | 0 |
| 30 Jun 13 | 612 | 26 | 173 | 0 |
Quality Earnings: ORIONINFU has high quality earnings.
Growing Profit Margin: ORIONINFU's current net profit margins (5.2%) are lower than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORIONINFU's earnings have grown by 2.6% per year over the past 5 years.
Accelerating Growth: ORIONINFU's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ORIONINFU had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.6%).
Return on Equity
High ROE: ORIONINFU's Return on Equity (14.4%) is considered low.